Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ASH 2012

8 - 11 Dec 2012
Massachusetts, Boston, United States of America
Clofarabine and other novel agents in AML; interview with Alan Burnett at ASH 20...
Prof Alan Burnett - Head of Haematology Department of Medical Genetics, Cardiff,...
Clofarabine and other novel agents in AML; interview with Alan Burnett at ASH 2012 ( Prof Alan Burnett - Head of Haematology Department of Medical Genetics, Cardiff, Wales )
16 Jan 2013
Advances in multiple myeloma from ASH 2012
Prof Thierry Facon - Centre Hospitalier Universitaire, France
Advances in multiple myeloma from ASH 2012 ( Prof Thierry Facon - Centre Hospitalier Universitaire, France )
20 Dec 2012
Expert overview of hot news in lymphoma from ASH 2012 (2/2)
Prof John Gribben, Prof Myron Czuczman, Prof Wolfram Brugger
Expert overview of hot news in lymphoma from ASH 2012 (2/2) ( Prof John Gribben, Prof Myron Czuczman, Prof Wolfram Brugger )
20 Dec 2012
Expert overview of hot news in lymphoma from ASH 2012 (1/2)
Prof John Gribben, Prof Myron Czuczman, Prof Wolfram Brugger
Expert overview of hot news in lymphoma from ASH 2012 (1/2) ( Prof John Gribben, Prof Myron Czuczman, Prof Wolfram Brugger )
20 Dec 2012
Advances in treatments for haematologic malignancies from the Sarah Cannon Resea...
Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA
Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (5/5) ( Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA )
20 Dec 2012
Advances in treatments for haematologic malignancies from the Sarah Cannon Resea...
Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA
Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (4/5) ( Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA )
20 Dec 2012
Advances in treatments for haematologic malignancies from the Sarah Cannon Resea...
Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA
Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (3/5) ( Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA )
20 Dec 2012
Advances in treatments for haematologic malignancies from the Sarah Cannon Resea...
Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA
Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (2/5) ( Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA )
20 Dec 2012
Advances in treatments for haematologic malignancies from the Sarah Cannon Resea...
Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA
Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (1/5) ( Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA )
20 Dec 2012
Multiple myeloma advances for the future suggested by phase I clinical research
Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA
Multiple myeloma advances for the future suggested by phase I clinical research ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )
20 Dec 2012
Advances in myeloid disease from ASH 2012 from the Sarah Cannon Research Institu...
Dr Michael Savona - Sarah Cannon Research Institute, Nashville, USA
Advances in myeloid disease from ASH 2012 from the Sarah Cannon Research Institute ( Dr Michael Savona - Sarah Cannon Research Institute, Nashville, USA )
20 Dec 2012
Highlights on multiple myeloma from ASH 2012
Professor Michel Delforge, Professor Meletios Dimopoulos
Highlights on multiple myeloma from ASH 2012 ( Professor Michel Delforge, Professor Meletios Dimopoulos )
18 Dec 2012
Expert overview of CLL from ASH 2012
Professor John Gribben, Professor Peter Hillman, Professor Kanti Rai
Expert overview of CLL from ASH 2012 ( Professor John Gribben, Professor Peter Hillman, Professor Kanti Rai )
18 Dec 2012
Expert overview of CLL in elderly from ASH 2012
Professor John Gribben, Professor Robin Foa, Professor Clemens Wendtner
Expert overview of CLL in elderly from ASH 2012 ( Professor John Gribben, Professor Robin Foa, Professor Clemens Wendtner )
18 Dec 2012
Expert overview of hot news in multiple myeloma from ASH 2012
Professor Jesus San Miguel, Professor Faith Davies, Professor Antonio Palumbo
Expert overview of hot news in multiple myeloma from ASH 2012 ( Professor Jesus San Miguel, Professor Faith Davies, Professor Antonio Palumbo )
18 Dec 2012
Advances in acute myeloid leukaemia (AML) for the elderly from ASH 2012
Professor Gert Ossenkoppele- VU University Medical Center, The Netherlands
Advances in acute myeloid leukaemia (AML) for the elderly from ASH 2012 ( Professor Gert Ossenkoppele- VU University Medical Center, The Netherlands )
18 Dec 2012
Anaemia in patients receiving chemotherapy; where are we now?
Prof Matti Aapro - Clinique de Genolier in Genolier, Switzerland
Anaemia in patients receiving chemotherapy; where are we now? ( Prof Matti Aapro - Clinique de Genolier in Genolier, Switzerland )
18 Dec 2012
Indolent lymphomas; advances from ASH 2012
Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany
Indolent lymphomas; advances from ASH 2012 ( Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany )
18 Dec 2012
Overview of multiple myeloma with Maria Victoria Mateos
Dr Maria-Victoria Mateos - University Hospital of Salamanca, Spain
Overview of multiple myeloma with Maria Victoria Mateos ( Dr Maria-Victoria Mateos - University Hospital of Salamanca, Spain )
18 Dec 2012
Advances and updates in treatments for myeloma presented at ASH 2012
Prof Keith Stewart - Mayo Clinic, Scottsdale, USA
Advances and updates in treatments for myeloma presented at ASH 2012 ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )
18 Dec 2012
Advances in myeloma at ASH 2012 (2/2)
Prof Gareth Morgan - The Royal Marsden Hospital, London
Advances in myeloma at ASH 2012 (2/2) ( Prof Gareth Morgan - The Royal Marsden Hospital, London )
18 Dec 2012
Advances in myeloma at ASH 2012 (1/2)
Prof Gareth Morgan - The Royal Marsden Hospital, London
Advances in myeloma at ASH 2012 (1/2) ( Prof Gareth Morgan - The Royal Marsden Hospital, London )
18 Dec 2012
Pre-Implantation genetic diagnosis
Dr Alison Lashwood - Guy's Hospital, London, UK
Pre-Implantation genetic diagnosis ( Dr Alison Lashwood - Guy's Hospital,  London, UK )
17 Dec 2012
The Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer ...
Dr Chaya Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA
The Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study ( Dr Chaya Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )
17 Dec 2012
MLN9708 in combination with lenalidomide and dexamethasone against multiple myel...
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
MLN9708 in combination with lenalidomide and dexamethasone against multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
17 Dec 2012
PACE Trial: Phase II trial of ponatinib in patients with chronic myeloid leukaem...
Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA
PACE Trial: Phase II trial of ponatinib in patients with chronic myeloid leukaemia (CML) ( Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA )
17 Dec 2012
Pomalidomide with low-dose vs. high-dose dexamathasone in refractory patients
Professor Meletios Dimopoulos - University of Athens, Greece
Pomalidomide with low-dose vs. high-dose dexamathasone in refractory patients ( Professor Meletios Dimopoulos - University of Athens, Greece )
16 Dec 2012
MLN9708 in combination with lenalidomide and dexamethasone
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
MLN9708 in combination with lenalidomide and dexamethasone ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
16 Dec 2012
History of epidermal stem cell use in the clinical setting
Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy
History of epidermal stem cell use in the clinical setting ( Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy )
14 Dec 2012
Exercise benefit to lifespan may be due to stem cell increase
Dr Mariusz Ratajczak - James Graham Brown Cancer Center, University of Louisvill...
Exercise benefit to lifespan may be due to stem cell increase ( Dr Mariusz Ratajczak - James Graham Brown Cancer Center, University of Louisville, Kentucky, USA )
14 Dec 2012
Histone deacetylases targeted as new strategy against graft versus host disease
Prof Sung Choi - University of Michigan, Ann Arbor, USA
Histone deacetylases targeted as new strategy against graft versus host disease ( Prof Sung Choi - University of Michigan, Ann Arbor, USA )
14 Dec 2012
Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leuka...
Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA
Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia ( Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA )
13 Dec 2012
Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell trans...
Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )
13 Dec 2012
The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab
Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, US...
The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab ( Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, USA )
13 Dec 2012
Uncovering new targets for treatment of chronic lymphocytic leukaemia
Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus, ...
Uncovering new targets for treatment of chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus, USA )
13 Dec 2012